BIOPARK SKY VIEW
"As a former Research Assistant at ULB and now part of iTeos’ team, a biotech company headquartered here, I am delighted to see that the BioPark has attracted so many companies and people active in the life sciences sector and that it has evolved into a dynamic working environment with excellent amenities and social activities. The park’s unique cluster reinforces collaborations, stimulates knowledge sharing and creativity."
— Margreet Brouwer, Senior Research Assistant, Iteos Therapeutics
"The BioPark’s cluster of innovative life sciences companies and their talented, multilingual and diverse work force together with the park’s state-of-the-art facilities make it an attractive place to invest. It provides an unique ecosystem of scientific, clinical and business expertise to progress early stage research and drug development through to stages offering excellent returns on investment with remarkable impact on society.”
— Chris Buyse, Managing Partner, Fund+
"The BioPark’s unique focus and expertise provide the perfect environment to grow your business into a fully-fledged, global company. The hands-on support we have received from the team, along with access to the BioPark’s outstanding services, have been a great help in establishing MTC as a distinguished, international cell therapy manufacturing company.”
— Denis Bedoret, President, MaSTherCell Global
Des macrophages, des souris et des hommes…Le Pr Stanislas Goriely vient d’obtenir un Win2Wal pour un ambitieux programme de recherche en immuno-oncologie. Au cœur de ce projet, des souris « humanisées » qui vont aider les chercheurs à mieux c...
Passer de la recherche académique à la spin-offButterFly DrugDevBooster est un nouveau programme de maturation proposé aux chercheurs par BioPark Incubator. Son objectif : favoriser et accélérer la transition entre la recherche académique et la cr...
Coolerr Bags InformationPromethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patie...
15.08.2019 / 12:00 > 4:00 PM 58 Greta Street
PROMETHERA BIOSCIENCES ANNOUNCES LATE-BREAKING DATA PRESENTATIONPromethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patie...
14.08.2019 / 7:00 > 12:00 PM ULiège - UMONS
